ACTRIMS 2022 | Ozanimod: long-term safety and efficacy in relapsing MS

Ozanimod, an S1P receptor modulator, was approved by the FDA in 2020 for the treatment of patients with relapsing forms of multiple sclerosis (MS). The approval was based on observations of reduced annualized relapse rate, fewer new or enlarging T2 lesions, and a greater reduction in the number of T1-weighted gadolinium-enhanced lesions, compared to treatment with interferon beta-1a in several randomized Phase III studies. Jeffrey A. Cohen, MD, Cleveland Clinic, Cleveland, OH, discusses ongoing long-term investigations of ozanimod following its approval. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.